Orla / Shutterstock.com
A tie-up between four leading pharmaceutical companies, the UK government and a health charity has created the world’s largest genetic research project. LSIPR’s Rory O’Neill looks at a new frontier for life sciences.
After decades of reliance on blockbuster drugs, pharmaceutical companies are increasingly having to face up to the challenge of diversifying their businesses.
As drug patents expire, the world’s leading drugmakers are coming under pressure to find new products and revenue streams. Some of the highest-selling drugs losing patent exclusivity in the US this year, for example, include Amgen’s Sensipar (cinacalcet) and GlaxoSmithKline’s Advair (fluticasone/salmeterol).
While a generic version of Sensipar has yet to hit the market, Mylan has won approval from the US Food and Drug Administration (FDA) for a generic Advair inhaler.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
genetic research, DNA, pharmaceuticals industry, drug patents, USFDA, mergers & acquisitions, UKRI, innovation, sequencing, precision medicines, SMEs
